{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:40:27Z","timestamp":1772826027685,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jcin.2019.05.028","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T13:58:44Z","timestamp":1564581524000},"page":"1538-1549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in\u00a0Coronary Artery Disease Patients Treated With Morphine"],"prefix":"10.1016","volume":"12","author":[{"given":"Francesco","family":"Franchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongwhi","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megha","family":"Kureti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Rivas Rios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Faz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Yaranov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latonya","family":"Been","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres M.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siva","family":"Suryadevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin M.","family":"Zenni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore A.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2019.05.028_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib2","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibition and Patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.05.028_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","article-title":"Antithrombotic therapy for patients with STEMI undergoing primary PCI","volume":"14","author":"Franchi","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2019.05.028_bib7","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib8","article-title":"Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Parodi","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2019.05.028_bib9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2013.10.068","article-title":"Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Hobl","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00392-015-0927-z","article-title":"Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers","volume":"105","author":"Hobl","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.05.028_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1160\/TH16-02-0102","article-title":"Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction","volume":"116","author":"Thomas","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2019.05.028_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.117.031678","article-title":"Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)","volume":"137","author":"McEvoy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2019.05.028_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.1975.tb00568.x","article-title":"Inhibition of gastric emptying and drug absorption by narcotic analgesics","volume":"2","author":"Nimmo","year":"1975","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jcin.2019.05.028_bib15","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.05.028_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","article-title":"Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap","volume":"170","author":"Alexopoulos","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2019.05.028_bib18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40265-013-0084-5","article-title":"Treatment of opioid-induced constipation: focus on the peripheral \u03bc-opioid receptor antagonist methylnaltrexone","volume":"73","author":"Rauck","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jcin.2019.05.028_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.283.3.367","article-title":"Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial","volume":"283","author":"Yuan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2019.05.028_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1124\/jpet.300.1.118","article-title":"Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial","volume":"300","author":"Yuan","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jcin.2019.05.028_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/17425255.2011.549824","article-title":"Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration","volume":"7","author":"Rotshteyn","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jcin.2019.05.028_bib22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/0091270004273491","article-title":"Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans","volume":"45","author":"Yuan","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jcin.2019.05.028_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0304-3959(99)00162-1","article-title":"Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study","volume":"83","author":"Yuan","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.jcin.2019.05.028_bib24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/DCR.0b013e3182092bde","article-title":"Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials","volume":"54","author":"Yu","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.jcin.2019.05.028_bib25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.05.028_bib26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jcin.2015.02.030","volume":"8","author":"Franchi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2019.05.028_bib27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","article-title":"Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 study","volume":"134","author":"Franchi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2019.05.028_bib28","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1161\/CIRCULATIONAHA.118.033983","article-title":"Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 Study","volume":"137","author":"Franchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2019.05.028_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor-inhibitor treatment in percutaneous coronary intervention","author":"Sibbing","year":"2019","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2019.05.028_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j..2002.384.doc.x","article-title":"Design and analysis of pilot studies: recommendations for good practice","volume":"10","author":"Lancaster","year":"2004","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.jcin.2019.05.028_bib31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.05.028_bib32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1160\/TH15-12-0944","article-title":"P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: the PRIVATE-ATLANTIC study","volume":"116","author":"Silvain","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2019.05.028_bib33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","article-title":"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly bindingoral P2Y(12) receptor antagonist, in healthy subjects","volume":"66","author":"Teng","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jcin.2019.05.028_bib34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/11599830-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies","volume":"51","author":"Husted","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcin.2019.05.028_bib35","article-title":"The MOVEMENT trial","volume":"8","author":"Holm","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2019.05.028_bib36","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1055\/s-0038-1675605","article-title":"Metoclopramide Administration as a Strategy to Overcome Morphine-Ticagrelor Interaction in Patients With Unstable Angina Pectoris\u2014The METAMORPHOSIS trial","volume":"118","author":"Sikora","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2019.05.028_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib38","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study","volume":"67","author":"Rollini","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.05.028_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"Valgimigli","year":"2012","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2019.05.028_bib40","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the CANTIC study","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879819312166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879819312166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:10:24Z","timestamp":1761847824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879819312166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":40,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1936879819312166"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2019.05.028","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in\u00a0Coronary Artery Disease Patients Treated With Morphine","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2019.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}